Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?

Djordje S Popovic; Dimitrios Patoulias; Theocharis Koufakis; Konstantinos Stavropoulos; Paschalis Karakasis; Ieva Ruža; Nikolaos Papanas; Manfredi Rizzo; Michael Doumas

doi:10.1016/j.jdiacomp.2024.108800

Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?

J Diabetes Complications. 2024 Aug;38(8):108800. doi: 10.1016/j.jdiacomp.2024.108800. Epub 2024 Jun 14.

Authors

Djordje S Popovic¹, Dimitrios Patoulias², Theocharis Koufakis², Konstantinos Stavropoulos², Paschalis Karakasis³, Ieva Ruža⁴, Nikolaos Papanas⁵, Manfredi Rizzo⁶, Michael Doumas²

Affiliations

¹ Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia. Electronic address: djordje.popovic@mf.uns.ac.rs.
² Second Propedeutic Department of Internal Medicine, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
³ Second Department of Cardiology, General Hospital "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Department of Endocrinology, Riga Eastern Clinical University Hospital, Latvia.
⁵ Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece.
⁶ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, Palermo, Italy.

PMID: 38889536
DOI: 10.1016/j.jdiacomp.2024.108800

Abstract

We sought to determine whether treatment with tirzepatide in type 2 diabetes mellitus (T2DM) patients can increase the odds for achieving normoglycemia, compatible with glycated hemoglobin levels lower than 5.7 %. We demonstrated that treatment with tirzepatide versus control increased the odds for achievement of normoglycemia by >16 times.

Keywords: Normoglycemia; Tirzepatide; Type 2 diabetes.

MeSH terms

Aged
Blood Glucose / analysis
Blood Glucose / drug effects
Blood Glucose / metabolism
Diabetes Mellitus, Type 2* / blood
Diabetes Mellitus, Type 2* / drug therapy
Female
Gastric Inhibitory Polypeptide
Glucagon-Like Peptide-2 Receptor
Glycated Hemoglobin* / analysis
Glycated Hemoglobin* / metabolism
Glycemic Control
Humans
Hypoglycemic Agents* / administration & dosage
Hypoglycemic Agents* / therapeutic use
Male
Middle Aged
Remission Induction*
Tirzepatide
Treatment Outcome

Substances

Hypoglycemic Agents
Glycated Hemoglobin
Tirzepatide
Blood Glucose
hemoglobin A1c protein, human
Glucagon-Like Peptide-2 Receptor
Gastric Inhibitory Polypeptide